KoroSero-EST-1 uuringu tulemusel leiti, et SARS-CoV-2 serolevimus Saaremal oli umbes 6 protsenti ja Tallinnas umbes 1,5%, kuid 80% SARS-CoV-2 seropositiivsetest põdesid haigust asümptomaatiliselt. Need isikud moodustavad SARS-CoV-2 nakkuse ja leviku mõistmise seisukohalt olulise rühma, kuna seni on ebaselge, miks nakatumine kulgeb osadel isikutel märkamatult.
KoroSero-EST-1 järeluuringu käigus selgitatakse välja, kas asümptomaatilistel isikutel on kujunenud immuunmälu antikehade ja T-rakulise immuunsuse osas ning võrreldakse seda kergelt ja raskelt COVID-19 põdenud haigetega ning selgitatakse, kas erineval raskustasemel haigust põdenud isikute põletikuliste markerite tasemed on omavahel erinevad. Lisaks uuritakse, kas nende isikute geneetiline taust on erinev.
According to the study of KoroSero-EST-1, the seroprevalence of SARS-CoV-2 in Saaremaa was about 6% and in Tallinn about 1.5%. However, 80% of seropositive subjects were asymptomatic. These subjects perform a significant proportion of all seropositive ones and it is important to determine the factors of asymptomatic course of the infection.
The aim of the KoroSero-EST-1 follow-up study is to find out if the asymptomatic seropositive subjects have developed immune memory for antibodies and T-cell immunity and compare the differences of the immune system and inflammation markers between seropositive subjects with a different course of the disease. In addition, to find out whether the genetic background of these subjects is different.